Current Trends in the Clinical Development of Antibody-Drug Conjugates in Oncology
Authors:
- 28 June 2018
- journal article
- review article
- Published by Springer Nature in Pharmaceutical Medicine
- Vol. 32 (4) , 259-273
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Inhibiting eukaryotic transcription. Which compound to choose? How to evaluate its activity?Transcription, 2011
- Microtubule-binding agents: a dynamic field of cancer therapeuticsNature Reviews Drug Discovery, 2010
- Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug ResistanceCancer Research, 2010
- Engineered therapeutic antibodies with improved effector functionsCancer Science, 2009
- Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistanceMolecular Cancer Therapeutics, 2009
- Therapeutic antibodies: successes, limitations and hopes for the futureBritish Journal of Pharmacology, 2009
- Novel Peptide Linkers for Highly Potent Antibody−Auristatin ConjugateBioconjugate Chemistry, 2008
- Paul Ehrlich's magic bullet concept: 100 years of progressNature Reviews Cancer, 2008
- Rapid identification of reactive cysteine residues for site-specific labeling of antibody-FabsJournal of Immunological Methods, 2008
- Anthrazykline in der KrebstherapieDrugs, 1997